Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1049874 | 0.74 | ACHE (0.42) | ACHEMGLLRECQL | |
| SCHEMBL16400892 | 0.74 | ACHE (0.42) | ACHEMGLLRECQL | |
| SCHEMBL28487276 | 0.72 | ACHE (0.36) | ACHEMGLLRECQL | |
| SCHEMBL5071144 | 0.70 | ACHE (0.39) | ACHEMGLLRECQL | |
| SCHEMBL3322504 | 0.70 | ACHE (0.34) | ACHEMGLLRECQLKMT2A | |
| SCHEMBL18262057 | 0.69 | FUCA1 (0.33) | — | |
| SCHEMBL29752582 | 0.67 | ACHE (0.46) | ACHEMGLLRECQLGAAKMT2A | |
| SCHEMBL644176 | 0.67 | — | — | |
| SCHEMBL21510078 | 0.66 | ACHE (0.35) | ACHERECQL | |
| SCHEMBL1218493 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4104380-A | Dibenzyl glycolic acid derivatives | WARNER-LAMBERT COMPANY (US) | 1978-08-01 | — | — | US | claimed |
| US-4076937-A | Dibenzyl glycolic acid derivatives | WARNER-LAMBERT COMPANY (US) | 1978-02-28 | — | — | US | claimed |
| US-20230364053-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PROSTATE CANCER OR BREAST CANCER | TOKYO METROPOLITAN GERIATRIC HOSPITAL AND INSTITUTE OF GERONTOLOGY (JP) | 2023-11-16 | — | — | US | disclosed |
| EP-4223293-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PROSTATE CANCER OR BREAST CANCER | Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology (JP) | 2023-08-09 | — | — | EP | disclosed |
| US-10959432-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2021-03-30 | — | — | US | disclosed |
| US-10757941-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2020-09-01 | — | — | US | disclosed |
| US-20200267986-A1 | Microbiocidal Oxadiazole Derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2020-08-27 | — | — | US | disclosed |
| US-10687533-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2020-06-23 | — | — | US | disclosed |
| EP-3439477-B1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2020-05-06 | — | — | EP | disclosed |
| US-20190274304-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-09-12 | — | — | US | disclosed |
| EP-3487843-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | Syngenta Participations AG (CH) | 2019-05-29 | — | — | EP | disclosed |
| EP-1136474-B1 | 1-Acetyl-5-bromo-4,6-dimethylindoline | SANKYO CO (JP) | 2003-11-26 | — | — | EP | disclosed |
| EP-0782986-B1 | NOVEL HETEROCYCLIC DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL USE THEREOF | SANKYO CO (JP) | 2003-07-02 | — | — | EP | disclosed |
| US-6489475-B2 | ENZYME INHIBITOR; LIPOPEROXIDATION INHIBITOR | SANKYO COMPANY, LIMITED (JP) | 2002-12-03 | — | — | US | disclosed |
| US-6414012-B1 | CARDIOVASCULAR DISORDERS; ANTICHOLESTEROL AGENTS | SANKYO COMPANY, LIMITED (JP) | 2002-07-02 | — | — | US | disclosed |
| EP-1136474-A1 | 1-Acetyl-5-bromo-4,6-dimethyl-indoline | SANKYO COMPANY LIMITED (JP) | 2001-09-26 | — | — | EP | disclosed |
| US-20010014740-A1 | Enzyme inhibitor; lipoperoxidation inhibitor | MATSUI HIROSHI (JP) | 2001-08-16 | — | — | US | disclosed |
| US-6127403-A | AN ENZYME INHIBITOR FOR TREATING ARTERIOSCLEROTIC LESIONS OF ARTERIOSCLEROSIS, HYPERLIPEMIA AND DIABETES, AS WELL AS ISCHEMIC DISEASES OF BRAIN, HEART | SANKYO COMPANY, LTD. (JP) | 2000-10-03 | — | — | US | disclosed |
| US-5990150-A | ACYLCOENZYME A:CHOLESTEROL ACYLTRANSFERASE (ACAT) INHIBITORS AND LIPOPEROXIDATION INHIBITORY ACTIVITY; ANTILIPEMIA; ARTERIOSCLEROSIS; ANTICHOLESTEROL AGENTS; ANTIISCHEMIC AGENTS; SIDE EFFECT REDUCTION | SANKYO COMPANY, LTD. (JP) | 1999-11-23 | — | — | US | disclosed |
| EP-0782986-A1 | NOVEL HETEROCYCLIC DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 1997-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010014740-A1 | Enzyme inhibitor; lipoperoxidation inhibitor | ACAT2, ACOX1, ACAT1 | ACHE 331/4885MGLL 223/4885RECQL 2911/4885 |
| US-10959432-B2 | Microbiocidal oxadiazole derivatives | PRF1, NOX1, ARG1 | ACHE 832/4885MGLL 106/4885RECQL 3778/4885 |
| US-10687533-B2 | Microbiocidal oxadiazole derivatives | PRF1, NOX1, ARG1 | ACHE 832/4885MGLL 106/4885RECQL 3778/4885 |
| US-10757941-B2 | Microbiocidal oxadiazole derivatives | PRF1, NOX1, ARG1 | ACHE 816/4885MGLL 109/4885RECQL 3776/4885 |
| US-20230364053-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PROSTATE CANCER OR BREAST CANCER | AR, NR5A1, CYP17A1 | ACHE 3613/4885MGLL 3684/4885RECQL 4297/4885 |
| US-20200267986-A1 | Microbiocidal Oxadiazole Derivatives | PRF1, NOX1, ARG1 | ACHE 832/4885MGLL 106/4885RECQL 3778/4885 |
| US-20190274304-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | PRF1, NOX1, ARG1 | ACHE 816/4885MGLL 109/4885RECQL 3776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.